MRSN · Categories · Form 4

MRSN - SEC Form 4 insider transactions

Mersana Therapeutics Inc. (MRSN) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for MRSN

• 153d
  Director Hack Andrew A. F. closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Hege Kristen closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Diaz Allene M. closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Dere Willard H closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  SVP, Chief Legal Officer Carvajal Alejandra closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  SVP, Chief Development Bala Mohan closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Alleva Lawrence M closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  President, CEO Huber Martin H. Jr. closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  VP, Chief Accounting Officer Mandelia Ashish closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Protopapas Anna closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  SVP, Chief Sci.&Tech. Officer Lowinger Timothy B closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  Director Mott David M closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 153d
  SVP, COO & CFO Deschuytner Brian closing all direct ownership in the company (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 223d
  SVP, Chief Development Officer Bala Mohan converted options into 250 shares and sold $762 worth of shares (77 units at $9.90), increasing direct ownership by 6% to 2,922 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 266d
  President, CEO Huber Martin H. Jr. converted options into 6,670 shares and sold $14,708 worth of shares (2,012 units at $7.31), increasing direct ownership by 95% to 9,572 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Hack Andrew A. F.

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Dere Willard H

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Diaz Allene M.

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Protopapas Anna

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Hege Kristen

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 360d
  SEC Form 4 filed by Director Mott David M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  VP, Chief Accounting Officer Mandelia Ashish converted options into 8,685 shares and sold $2,061 worth of shares (3,554 units at $0.58), increasing direct ownership by 10% to 57,519 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  Director Protopapas Anna sold $5,009 worth of shares (8,637 units at $0.58) and converted options into 21,250 shares, increasing direct ownership by 8% to 168,041 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  SVP, Chief Sci.&Tech. Officer Lowinger Timothy B converted options into 19,791 shares and sold $4,668 worth of shares (8,048 units at $0.58), increasing direct ownership by 5% to 257,673 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  President, CEO Huber Martin H. Jr. sold $2,618 worth of shares (4,514 units at $0.58) and converted options into 11,062 shares, increasing direct ownership by 6% to 122,875 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  SVP, COO & CFO Deschuytner Brian converted options into 20,833 shares and sold $4,913 worth of shares (8,470 units at $0.58), increasing direct ownership by 11% to 121,393 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  SVP, Chief Legal Officer Carvajal Alejandra converted options into 12,500 shares and sold $2,956 worth of shares (5,096 units at $0.58), increasing direct ownership by 10% to 78,296 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 507d
  SVP, Chief Development Officer Bala Mohan converted options into 14,583 shares and sold $3,445 worth of shares (5,939 units at $0.58), increasing direct ownership by 14% to 68,872 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 508d
  Director Protopapas Anna converted options into 16,750 shares and sold $3,900 worth of shares (6,191 units at $0.63), increasing direct ownership by 7% to 155,428 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 508d
  VP, Chief Accounting Officer Mandelia Ashish converted options into 4,783 shares and sold $1,128 worth of shares (1,791 units at $0.63), increasing direct ownership by 6% to 52,388 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 508d
  SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold $1,130 worth of shares (1,794 units at $0.63) and converted options into 4,792 shares, increasing direct ownership by 1% to 245,930 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 508d
  SVP, COO & CFO Deschuytner Brian converted options into 6,250 shares and sold $1,469 worth of shares (2,331 units at $0.63), increasing direct ownership by 4% to 109,030 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 508d
  SVP, Chief Legal Officer Carvajal Alejandra converted options into 2,500 shares and sold $600 worth of shares (952 units at $0.63), increasing direct ownership by 2% to 70,892 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  Director Protopapas Anna converted options into 31,250 shares and sold $7,612 worth of shares (11,534 units at $0.66), increasing direct ownership by 16% to 144,869 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  VP, Chief Accounting Officer Mandelia Ashish converted options into 2,646 shares and sold $665 worth of shares (1,007 units at $0.66), increasing direct ownership by 3% to 49,396 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  SVP, Chief Sci.&Tech. Officer Lowinger Timothy B converted options into 9,375 shares and sold $2,299 worth of shares (3,483 units at $0.66), increasing direct ownership by 2% to 242,932 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  SVP, COO & CFO Deschuytner Brian converted options into 10,000 shares and sold $2,451 worth of shares (3,713 units at $0.66), increasing direct ownership by 6% to 105,111 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  SVP, Chief Legal Officer Carvajal Alejandra sold $2,198 worth of shares (3,330 units at $0.66) and converted options into 8,958 shares, increasing direct ownership by 9% to 69,344 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 509d
  SVP, Chief Development Officer Bala Mohan converted options into 8,750 shares and sold $2,147 worth of shares (3,253 units at $0.66), increasing direct ownership by 10% to 60,228 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 521d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 532d
  Large owner Ecor1 Capital, Llc disposed of 8,036,688 shares (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 587d
  SVP, Chief Development Officer Bala Mohan converted options into 6,250 shares and sold $3,580 worth of shares (1,884 units at $1.90), increasing direct ownership by 9% to 54,731 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 609d
  SVP, COO & CFO Deschuytner Brian converted options into 50,000 shares and sold $27,150 worth of shares (13,687 units at $1.98), increasing direct ownership by 62% to 94,824 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 609d
  SVP, Chief Legal Officer Carvajal Alejandra converted options into 50,000 shares and sold $27,150 worth of shares (13,687 units at $1.98), increasing direct ownership by 133% to 63,716 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 609d
  SVP, Chief Development Officer Bala Mohan converted options into 50,000 shares and sold $27,150 worth of shares (13,687 units at $1.98), increasing direct ownership by 258% to 50,365 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 609d
  VP, Chief Accounting Officer Mandelia Ashish sold $16,298 worth of shares (8,216 units at $1.98) and converted options into 30,000 shares, increasing direct ownership by 84% to 47,757 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 609d
  SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold $27,150 worth of shares (13,687 units at $1.98) and converted options into 50,000 shares, increasing direct ownership by 18% to 235,642 units (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 613d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 633d
  President, CEO Huber Martin H. Jr. converted options into 166,750 shares and sold $88,744 worth of shares (50,423 units at $1.76) (SEC Form 4)

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 706d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Hack Andrew A. F.

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Protopapas Anna

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Mott David M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Hege Kristen

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Diaz Allene M.

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Dere Willard H

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 726d
  SEC Form 4 filed by Director Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 796d
  SEC Form 4 filed by Alleva Lawrence M

  4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
• 843d
  SEC Form 4 filed by Mandelia Ashish (Amendment)

  4/A - Mersana Therapeutics, Inc. (0001442836) (Issuer)

Other MRSN categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends